Glenmark gets ANDA nod for Deferasirox tablets for oral suspension


Glenmark Pharmaceuticals















Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.

According to IQVIA sales data for the 12 months ending November 2019, the Exjade Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg market achieved annual sales of ~$106.4 mn.

Glenmark’s current portfolio consists of 165 products authorized for distribution in the US marketplace and 43 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals Ltd is currently trading at Rs344.65, up by Rs5 or 1.47% from its previous closing of Rs339.65 on the BSE.

The scrip opened at Rs342.25 and has touched a high and low of Rs349.20 and Rs342.25 respectively.




About Gosip4U

Gosip4U is the digital wing of india - India's leading media and communications group with its interests spanning across country.

0 comments:

Post a Comment

Please add comment